Latest Regulatory Development News

Citigold Corporation Limited has faced intense ASX scrutiny following an adverse auditor opinion on its half-year financials, centering on a $20 million impairment of exploration assets. The company defends its valuation approach despite funding uncertainties and regulatory questions.

Westpac Banking Corporation reported a modest 1% decline in net profit to AUD 3.317 billion for the six months ended March 2025, maintaining its interim dividend and advancing key digital and sustainability initiatives.

Santos Limited’s 2024 Annual Report reveals a 5% drop in production and a 9% decline in sales revenue, yet highlights significant progress in carbon capture and storage projects and emissions reduction targets.

Highfield Resources has made significant progress on its strategic transaction with Yankuang Energy and Beijing Energy, securing key regulatory approvals and restructuring its financing amid disciplined cost management.

Basin Energy has completed a strategic acquisition of uranium and green energy metals assets in Scandinavia, revealing exceptional initial exploration results and expanding its footprint in the Athabasca Basin.

betr Entertainment has successfully raised $130 million through a fully underwritten equity offer priced at a 13.7% premium, underpinning its strategic acquisition of PointsBet and positioning for growth in the Australian wagering market.

Novonix Limited advances its synthetic graphite production with Riverside commissioning and a new Chattanooga plant site, while winning a preliminary US trade case against Chinese imports and appointing Michael O’Kronley as CEO.

Kingsrose Mining advances its Fennoscandian exploration with high-grade discoveries and strategic acquisition of the Jakon project, supported by robust funding from BHP.

Silver Mines Limited reports steady progress on its flagship Bowdens Silver Project and initiates diamond drilling at the Elsienora Gold Project, while navigating complex regulatory hurdles in New South Wales.

Actinogen Medical advances its XanaMIA phase 2b/3 Alzheimer’s trial with faster patient enrolment and expands clinical sites, while achieving a pivotal FDA meeting outcome for its depression program. The company maintains a strong cash position, supporting ongoing development and commercialization efforts.

Imugene Limited reports encouraging Phase 1b results for azer-cel in lymphoma, secures FDA Fast Track status, and strengthens patent portfolio while raising A$20 million to fuel ongoing immuno-oncology programs.

Piche Resources has extended its Cerro Chacon gold-silver mineralised corridor to 14km and identified multiple high-grade uranium zones at Sierra Cuadrada, setting the stage for an 8,000m drilling campaign in 2Q 2025.